Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5962435 A
Publication typeGrant
Application numberUS 08/854,647
Publication dateOct 5, 1999
Filing dateMay 12, 1997
Priority dateDec 10, 1993
Fee statusPaid
Also published asUS5677291
Publication number08854647, 854647, US 5962435 A, US 5962435A, US-A-5962435, US5962435 A, US5962435A
InventorsSimon J. T. Mao, Mark T. Yates, Roger A. Parker
Original AssigneeHoechst Marion Roussel, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
US 5962435 A
Abstract
A method of lowering plasma cholesterol level in a patient with hypercholesterolemia, by administration of a compound of formula (1) ##STR1## wherein: R1, R2, R3 and R4 are each independently a C1 -C6 alkyl group;
Z is a thio, oxy or methylene group;
A is a C1 -C4 alkylene group; and
R5 is a C1 -C6 alkyl or --(CH2)n --(Ar)
wherein n is an integer 0, 1, 2 or 3; and Ar is phenyl or napthyl unsubstituted or substituted with one to three substituents selected from the group consisting of hydroxy, methoxy, ethoxy, chloro, fluoro or C1 -C6 alkyl.
Images(9)
Previous page
Next page
Claims(11)
What is claimed is:
1. A compound selected from the group consisting of
2,6-Di-t-butyl-4 (4-chlorophenyldimethylsilyl)methyloxy!phenol;
2,6-Di-t-butyl-4 dimethyl-4-fluorophenylsilyl)methyloxy!phenol;
2.
2. 6-Di-t-butyl-4 dimethylphenylsilyl)methyloxy!phenol;
2,6-Dimethyl-4 (dimethylphenylsilyl)methyloxy!phenol;
2-t-butyl-6-methyl-4 (dimethylphenylsilyl)methylthio!phenol;
2,6-Di-t-butyl-4- (dimethyl-2,5-dimethoxyphenylsilyl)methyloxy!phenol;
2,6-Di-t-butyl-4- (dimethyl-2,3-dimethoxyphenylsilyl)methyloxy!phenol;
2,6-Di-t-butyl-4- (dimethyl-4-t-butylphenylsilyl)methyloxy!phenol; and
2,6-Di-t-butyl-4- (benzyldimethylsilyl)methyloxy!phenol. 2. A compound according to claim 1 wherein the compound is 2,6-Di-t-butyl-4 (4-chlorophenyldimethylsilyl)methyloxy!phenol.
3. A compound according to claim 1 wherein the compound is 2,6-Di-t-butyl-4 dimethyl-4-fluorophenylsilyl)methyloxy!phenol.
4. A compound according to claim 1 wherein the compound is 2,6-Di-t-butyl-4 dimethylphenylsilyl)methyloxy!phenol.
5. A compound according to claim 1 wherein the compound is 2,6-Dimethyl-4 (dimethylphenylsilyl)methyloxy!phenol.
6. A compound according to claim 1 wherein the compound is 2-t-butyl-6-methyl-4 (dimethylphenylsilyl)methylthio!phenol.
7. A compound according to claim 1 wherein the compound is 2,6-Di-t-butyl-4- (dimethyl-2,5-dimethoxyphenylsilyl)methyloxy!phenol.
8. A compound according to claim 1 wherein the compound is 2,6-Di-t-butyl-4- (dimethyl-2,3-dimethoxyphenylsilyl)methyloxy!phenol.
9. A compound according to claim 1 wherein the compound is 2,6-Di-t-butyl-4- (dimethyl-4-t-butylphenylsilyl)methyloxy!phenol.
10. A compound according to claim 1 wherein the compound is 2,6-Di-t-butyl-4- (benzyldimethylsilyl)methyloxy!phenol.
Description

This is a division, of application Ser. No. 08/582,835, filed Jan. 2, 1996, now U.S. Pat. No. 5,677,291 which is a continuation-in-part of application Ser. No. 08/409,104 filed Mar. 27, 1995, now abandoned; which is a continuation of application Ser. No. 08/165,281 filed Dec. 10, 1993, now abandoned; which is herein incorporated by reference.

Coronary heart disease (CHD) remains the leading cause of death in the industrialized countries. Despite recent declines in CHD mortality, CHD is still responsible for more than 500,000 deaths in the U.S. annually. It is estimated that CHD, directly and indirectly, costs the U.S. more than $100 billion a year. The primary cause of CHD is atherosclerosis, a disease characterized by the deposition of lipids in the arterial vessel wall, resulting in a narrowing of the vessel passages and ultimately hardening the vascular system.

Atherosclerosis as manifested in its major clinical complication, ischaemic heart disease, is thought to begin with local injury to the arterial endothelium followed by proliferation of arterial smooth muscle cells from the medial layer to the intimal layer along with deposition of lipid and accumulation of foam cells in the lesion. As the atherosclerotic plaque develops, it progressively occludes more and more blood vessel and can eventually lead to ischaemia or infarction. Therefore, it is desirable to provide a method of inhibiting the progression of atherosclerosis in patients in need thereof.

Hypercholesterolemia is an important risk factor associated with CHD. For example, in December 1984, a National Institute of Health Consensus Development Conference Panel concluded that lowering plasma cholesterol levels (specifically blood levels of low-density lipoprotein cholesterol) will definitely reduce the risk of heart attacks due to CHD. Serum lipoproteins are the carriers for lipids in the circulation. They are classified according to their density: chylomicrons, very low-density lipoproteins (VLDL), low density lipoproteins (LDL) and high-density lipoproteins (HDL). Chylomicrons mainly participate in transporting dietary triglycerides and cholesterol from the intestine to adipose tissue and liver. VLDL deliver endogenously synthesized triglycerides from liver to adipose and other tissues. LDL transports cholesterol to peripheral tissues and regulate endogenous cholesterol levels in those tissues. HDL transports cholesterol from peripheral tissues to the liver. Arterial wall cholesterol is derived almost exclusively from LDL (Brown and Goldstein, Ann. Rev. Biochem. 52, 223 (1983); Miller, Ann. Rev. Med. 31, 97 (1980)). In patients with low levels of LDL, the development of atheroscherosis is rare. Accordingly, it is desirable to provide a method for reducing plasma cholesterol in patients with hypercholesterolemia or at risk of developing hypercholesterolemia.

Elevated cholesterol levels are also associated with a number of disease states, including restenosis, angina, cerebral arteriosclerosis, and xanthoma. It is desirable to provide a method for reducing plasma cholesterol in patients with, or at risk of developing, restenosis, angina, cerebral arteriosclerosis, xanthoma, and other disease states associated with elevated cholesterol levels.

SUMMARY OF THE INVENTION

The present invention relates to the use of certain 2,6-di-alkyl-4-silyl-phenols to lower cholesterol levels in patients with hypercholesterolemia. The present invention also relates to the use of certain 2,6-di-alkyl-4-silyl-phenols to lower cholesterol levels in patients with restenosis, angina, cerebral artheriosclerosis, xanthoma and other disease states associated with elevated cholesterol levels.

The present invention relates to a method for lowering plasma cholesterol in a patient by administration of a compound of the formula of (1) ##STR2## wherein: R1, R2, R3 and R4 are each independently a C1 -C6 alkyl group;

Z is a thio, oxy or methylene group;

A is a C1 -C4 alkylene group; and

R5 is a C1 -C6 alkyl or --(CH2)n --(Ar)

wherein n is an integer 0, 1, 2 or 3; and Ar is phenyl or napthyl unsubstituted or substituted with one to three substituents selected from the group consisting of hydroxy, methoxy, ethoxy, chloro, fluoro or C1 -C6 alkyl.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "C1-C 6 alkyl" refers to a saturated hydrocarbyl radical of straight, branched or cyclic configuration made up of from one to six carbon atoms. Included within the scope of this term are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tertiarybutyl, n-pentyl, n-hexyl, cyclohexyl and the like.

Likewise, the term "C1 -C4 alkylene" refers to a saturated hydrocarbyldiyl radical of straight or branched configuration made up of from one to four carbon atoms. Included within the scope of this term are methylene, 1,2-ethane-diyl, 1,1-ethane-diyl, 1,3-propane-diyl, 1,2-propane-diyl, 1,3-butane-diyl, 1,4-butane-diyl and the like.

In those instances wherein R5 is a --(CH2)n--(Ar) radical, the "--(CH2)n--" moiety represents a saturated hydrocarbyldiyl radical of straight chain configuration. The term "n" is defined as an integer 0, 1, 2 or 3. The moiety "--(CH2)n --" thus represents a bond, methylene, 1,2-ethanediyl or 1,3-propanediyl. The "--(Ar)" moiety represents an aryl radical defined as a substituted or unsubstituted phenyl or napthyl group. In those instances wherein the --(Ar) moiety is a substituted aryl, the phenyl or napthyl can bear from 1 to 3 substituents in any position otherwise occupied by a hydrogen atom. Substituents are selected from the group consisting of hydroxy, methoxy, ethoxy, chloro, fluoro and C1 -C6 alkyl group. Specifically included within the scope of the term "--(CH2)n --(Ar)" are phenyl; napthyl; phenylmethyl; phenylethyl; 3,4,5-trihydroxyphenyl; 3,4,5-trimethoxyphenyl; 3,4,5-triethoxyphenyl; 4-chlorophenyl; 4-methylphenyl; 3,5-di-tertiarybutyl-4-hydroxyphenyl;4-fluorophenyl; 4-chloro-1-naphthyl; 2-methyl-1-naphthylmethyl; 2-naphthylmethyl; 4-chlorophenylmethyl; 4-tertiarybutylphenyl; 4-tertiarybutylphenylmethyl and the like.

The compounds of formula (1) can be prepared by utilizing procedures and techniques well known and appreciated by one of ordinary skill in the art. A general synthetic scheme for preparing compounds of formula (1) wherein Z is sulfur or oxygen is set forth in Scheme A, wherein all substituents, unless otherwise indicated, are previously defined. ##STR3##

In general, a phenol of structure la can be prepared by reacting the appropriate 2,6-dialkyl-4-mercaptophenol or 2,6-dialkylhydroquinone of structure 2(or suitably protected derivatives) with a non-nucleophilic base, such as sodium hydride, potassium carbonate or cesium carbonate, and the appropriate haloalkylenesilane of structure 3, such as the appropriate chloroalkylenesilane, in a suitable aprotic solvent, such as acetonitrile, dimethylformamide or dimethylacetamide, or in an aqueous solvent, such as water/2-butanone.

Starting materials for use in the general synthetic procedure outlined in Scheme A are readily available to one of ordinary skill in the art. For example, certain phenol starting materials for various compounds of formula (1) wherein Z is sulfur, such as 2,6-di-teriarybutyl-4-mercaptophenol, are described in U.S. Pat. No. 3,576,883, U.S. Pat. No. 3,952,064, U.S. Pat. No. 3,479,407 and in Japanese Patent Application 73-28425. Also, silyl starting materials for various compounds of formula (1), such as (trimethylsilyl)-methyl iodide, (trimethylsilyl)methyl bromide, (trimethyl-silyl)methyl chloride, (1-chloropropyl)trimethylsilane, are described in Synthesis 4, 318-19 (1988) and J. Am. Chem. Soc. 105, 5665-75 (1983). Additional methods for preparing suitable silanes include a Grignard reaction eg. 4-Bromoanisole is reacted with magnesium metat to form the Grignard reagent and the reagent is reacted with chlorodimethyl chloromethy (silane to give chloromethyldimethyl-4-methoxy phenyl silane. ##STR4## Alternatively, anisole may be lithiated by reacton with Δ-Butylithium and the lithio compound formed is reacted with chlorodimethyl chloromethyl silane to give chloromethyl dimethyl-2-methoxyphenyl silane. ##STR5##

In those instances where the 1-phenol functionality of a compound of structure 2 may react with the compounds of structure 3 under the conditions of the reaction, the 1-phenol functionality of compound of structure 2 may be blocked with standard phenol blocking agents which are well known and appreciated in the art. The selection and utilization of particular blocking groups are well known to one of ordinary skill in the art. In general, blocking groups should be selected which adequately protect the phenol in question during subsequent synthetic steps and which are readily removable under conditions which will not cause degradation of the desired product.

Examples of suitable phenol protecting groups are ethers, such as methoxymethyl, 2-methoxyethoxymethyl, tetrahydro-pyranyl, t-butyl and benzyl; silyl ethers, such as trimethylsilyl and t-butyldimethylsilyl; esters, such as acetate and benzoate; carbonates, such as methylcarbonate and benzylcarbonate; as well as sulfonates, such as methanesulfonate and toluenesulfonate.

In those instances where R1 and R2 are each t-butyl, the reaction of Scheme A may be conveniently carried out without blocking of the 1-phenol functionality.

The following examples present typical syntheses as described in Scheme A. These examples are understood to be illustrative only and are not intended to limit the scope of the present invention in any way. As used herein, the following terms have the indicated meanings: "g" refers to grams; "mmol" refers to millimoles; "mL" refers to milliliters; "bp" refers to boiling point; " C." refers to degrees Celsius; "mm Hg" refers to millimeters of mercury; "mp" refers to melting point; "mg" refers to milligrams; "μM" refers to micromolar; "μg" refers to micrograms.

EXAMPLE 1 2,6-Di-t-butyl-4 (dimethylphenylsilyl)methylthio!phenol (Compound A)

Mix 2,6-di-t-butyl-4-mercaptophenol (2.4 g, 10 mmol), potassium carbonate (1.4 g, 10 mmol), chloromethyldimethylphenylsilane (1.9 g, 10 mmol) and dimethylformamide (50 mL) and stir overnight at room temperature under argon atmosphere. Dilute the mixture with ice-water and extract with ethyl ether. Wash the ethereal layer with water, then brine, filter through flourosil-Na2 SO4, and evaporate to an orange oil (3.5 g). Purify the product by first distilling (bp 160-170 C. @ 0.1 mm Hg), then subjecting to silica gel chromatography (CCl4 :CHCl3 /1:1) to obtain the title compound as a light yellow oil which slowly crystallizes to a white waxy solid (2.3 g, 59%). Anal. Calcd for C23 H34 OSSi: C, 71.44; H, 8.86; S, 8.29; Found: C, 71.14; H, 8.86; S, 7.98.

EXAMPLE 2 2,6-Di-t-butyl-4 (dimethyldodecylsilyl)methylthio!phenol (Compound B)

Mix 2,6-di-t-butyl-4-mercaptophenol (2.4 g, 10 mmol), potassium carbonate (1.7 g, 12.3 mmol), chloromethyldodecyldimethylsilane (2.8 g, 10 mmole) and dimethylformamide (50 mL) and stir overnight at room temperature under argon atmosphere. Dilute the mixture with ice-water, acidify with aqueous hydrochloric acid and extract with ethyl ether. Wash the ethereal layer with water, then brine, filter through fluorosil-Na2 SO4 and evaporate to an orange semi-solid (4.0 g). Purify the product by first distilling (180-200 C. @ 0.1 mm Hg) then subjecting to silica gel chromatography (CCl4) to obtain the title compound as a colorless oil which slowly crystallizes.

Anal. Calcd for C29 H54 OSSi: C, 72.73; H, 11.37; S, 6.70; Found: C, 71.26; H, 11.34; S, 6.93.

EXAMPLE 3 2,6-Di-t-butyl-4 (trimethylsilyl)methylthio!phenol (Compound C)

Mix 2,6-di-t-butyl-4-mercaptophenol (2.4 g, 10 mmol), potassium carbonate (1.4 g, 10 mmol), and dimethylacetamide (50 mL) and stir at room temperature under argon atmosphere. Add chloromethyltrimethylsilane (1.3 g, 10 mmol) and stir overnight. Warm on a steam bath for 2 hours, cool, and dilute with water. Extract with ethyl ether, dry, evaporate to a light yellow solid (2.8 g) and recrystallize (CH3 CN) to give 1.1 g (34%) of the title compound; mp 100-101 C.

Anal. Calcd for C18 H32 OSSi: C, 66.60; H, 9.88; S, 9.88; Found: C, 66.83; H, 10.05; S. 9.91.

EXAMPLE 4 2,6-Dimethyl-4 (trimethylsilyl)methyloxy!phenol (Compound D)

Mix 2,6-dimethylhydroquinone (1.4 g, 10 mmol), potassium carbonate (1.4 g, 10 mmol), chloromethyltrimethylsilane (1.9 g, 10 mmol) and dimethylformamide (50 mL). Stir at room temperature under inert atmosphere until the reaction is complete. Dilute the mixture with ice-water and extract with ethyl ether. Wash the ethereal layer with water, then brine and filter through fluorosil-Na2 SO4. Evaporate to give the title compound and purify by silica gel chromatography.

EXAMPLE 5 2,6 Di-t-butyl-4 (4-chlorophenyldimethylsilyl)methyloxy!phenol (Compond E) ##STR6## Reflux 2,6- di-t-butylbenzhydroquinone (13.7 g, 61.6 mM), potassium carbonate (9.4 g, 68 mM), chloromethyl (4-chlorophenyl) dimethyl silane (14.9 g, 68 mM) and a catalytic amount of potassium iodide in acetonitrile (200 ml) for three days under N2. Filter off solids and evaporate. Redissolve in ethyl acetate and wash with water, then brine, dry with anhydrous magnesium sulfate, filter and evaporate. The resulting orange oil can be purified by distilling to 135 C. @ 0.1 mm Hg to remove lower boiling impurities followed by distillation of product (bp C. @ 0.1 mm Hg). The product which crystallizes on standing can be recrystallized from hexane to give fine white needles (7.4 g, 27% yield ) mp102-105 C.

Anal. Calcd. for C23 H33 CIO2 Si: C, 68.20; H, 8.21 Found: C, 68.39; H, 8.13 NMR (CDC13): 7.53 (d, 2H, J 8.3), 7.34 (d, 2H, J 8.3) 6.79 (s, 2H), 4.73 (s, 1H), 3.71 (s, 2H), 1.42 (s, 18H), 0.41 (s, 6H).

EXAMPLE 6 2,6 Di-t-butyl-4 dimethyl-4-fluorophenylsilyl)methyloxy!phenol (Compound F) ##STR7## Reflux 2,6-di-t-butylbenzhydroquinone (10.0 g, 45 mM), potassium carbonate (6.2 g, 45 mM) and dimethyl (4-flurophenyl) iodomethylsilane (13.2 g, 45 mM) in acetonitrile (150 ml) for three days under nitrogen. Filter off solids and evaporate. Redissolve in ethyl acetate and wash with water, then brine, dry with anhydrous magnesium sulfate, filter and evaporate to a very pale yellow oil which crystallizes on standing. This material could be recrystallized from methanol to give a white crystalline solid (5.9 g, 34% yield) mp 90-93 C.

Anal. calcd. for C23 H33 FO2 Si: C, 71.09; H, 8.86 Found: C. 70.96; H, 8.58 NMR (CDCI3): 7.58 (dd, 2H, J 8.5, 6.2), 7.10-7.04(m, 2H), 6.80(s, 2H), 4.73 (s, 1H), 3.71 (si, 2H), 1.43 (s, 18H), 0.41 (s, 6H).

EXAMPLE 7 2,6-Di-t-butyl-4 dimethylphenylsilyl)methyloxy!phenol (Compound G) ##STR8## Reflux 2,6-di-t-butylbenzhydroquinone (5.43 g, 24.4 mM), potassium carbonate (3.7 g, 26.8 mM) and dimethyl (iodomethyl) phenylsilane (7.4 g, 26.8 mM) in acetonitrile (125 ml) overnight under N2. Filter off solids and evaporate. Redissolve in ethyl acetate and wash with water, then brine, dry with anhydrous magnesium sulfate, filter and evaporate. The resulting orange oil can be purified by distilling to 135 C.@ 0.1 mm Hg. to remove lower boiling impurities followed by distillation of product (bp 155-165 C@ 0.1 mm Hg). The product which crystallizes on standing can be recrystallized from methanol to give a white solid (5.8g, 64% yield) mp 82-83 C.

Anal. Calcd. for C23 H34 O2 Si: C, 74.54; H, 9.25 Found: C, 74.51; H, 9.28 NMR (CDCl3): 7.64-7.58 (m, 2H), 7.42-7.32 (m, 2H), 6.80 (s, 2H), 4.72 (s, 1H), 3.73 (s, 2H), 1.42 (s, 18H), 0.42 (s, 6H)

EXAMPLE 8 2,6-Di-t-butyl-4 (dimethyl-4-methoxy phenylsilyl)methyloxy!phenol (Compound H) ##STR9## Reflux 2,6-di-t-butylbenzhydroquinone (13.7 g, 61.1 mM), potassium carbonate (9.4 g, 68 mM), chloromethyl (dimethyl)-4-methoxyphenylsilane (14.6 g, 68 mM) and a catalytic amount of potassium iodide in acetonitrile (200 ml) for three days under N2. Filter off solids and evaporate. Redissolve in ethyl acetate and wash with water, then brine, dry with anhydrous magnesium sulfate, filter and evaporate. The resulting orange oil can be purified by distilling to 135 C. @ 0.1 mm Hg to remove lower boiling impurities followed by distillation of product (bp 155-165 C. @ 0.1 mm Hg). The product which crystallizes on standing can be recrystallized from hexane to give a white solid (4.9 g, 19% yield) mp 122-123 C.

Anal. Calcd. for C24 H36 O3 Si: C, 71.95; H, 9.06 Found: C, 71.80; H, 9.00 NMR (CDCl13): 7.53 (d, 2H, J 8.6), 6.93 (d, 2H, J8.6), 6.80 (s, 2H), 4.71 (s, 1H), 3.81 (s, 3H), 3.70 (s, 2H), 1.42 (s, 18H), 0.39 (s, 6H).

EXAMPLE 9 2,6-Dimethyl-4 (dimethylphenylsilyl)methyloxy!phenol (Compound I) ##STR10## Reflux 2,6-dimethylhydroquinone (10.0 g, 72.4 mmol), potassium carbonate (10.0 g, 72.4 mmol), and dimethyl(chloromethyl)phenylsilane (13.4 g, 72.4 mmol in acetonitrile (150 ml) for 72 hours under argon. The mixture is allowed to cool and diluted with water and extracted into ether. The oil is distilled at 145 to 160 C. @ 0.1 mm Hg. to give 4.9 g. of a light yellow oil.

Anal. Calcd. for C17 H22 O2 Si: C, 71.28; H, 7.74 Found: C, 71.27; H, 7.74

EXAMPLE 10 2-t-butyl-6-methyl-4 (dimethylphenylsilyl)methylthio!phenol (Compond J) ##STR11## Reflux 2-t-butyl-6-methyl-4-mercaptophenol (11.8 g, 60.1 mmol), potassium bicarbonate (6.0 g, 11.8 mmol), and dimethyl(chloromethyl)phenylsilane (11.1 g 60.1 mmol) in isopropanol (150 ml) for 24 hours under argon. The mixture is allowed to cool and diluted with water and extracted into ether. The ether layer was evaporated to dryness to give 21.9 g of an oil. The oil is distilled at 145-160 C. (0.1 mmHg) to give 5.5 g of a light yellow oil.

Anal. Calcd for C20 H28 OSSi: C, 69.71; H, 8.19 Found: C, 69.76, H, 8.20

EXAMPLE 11

2,6-Di-t-butyl-4- (dimethy 1-2-methoxyphenylsilyl)methyloxy!phenol (Compound K)

A mixture of chloromethyldimethyl (2-methoxy) phenylsilane (27.2 g, 0.127 mole), sodium iodide (19 g, 0.127 mole) and acetonitrile (350 mL) was heated at reflux for 28 h. The mixture was cooled to ambient temperature and 2,6-di-t-butyl- 1, 4-hydroquinone (31.5 g, 0.14 mole) and potassium carbonate (20.8 g, 0.15) mole were added. The mixture was refluxed under a nitrogen atmosphere for 7 days. The mixture was cooled, poured into water (400 mL) and ethyl acetate (400 mL) and the organic layer was separated. The organic layer was evaporated and the residue was chromatographed on silica gel (hexane/ethyl acetate 9/1). The chromatographed product was recrystallized (methanol) to give the product (15.6 g, 31%) as a white solid, mp 89-90 C.

Anal. Calcd for C24 H36 O3 Si: C, 71.95; H, 9.06 Found: C, 71.84; H, 9.05.

EXAMPLE 12 2,6-Di-t-butyl-4- (dimethyl-2, 5-dimethoxyphenylsilyl) methyloxy!phenol (Compound L)

Preparation as for previous compound using chloromethyl dimethyl-2, 5-dimethoxy-phenyl silane (14g, 57mmole) as the silane to give a white solid, mp 103-04 C.

Anal. Calcd for C25 H38 O4 Si: C, 69.72; H, 8.89 Found: C, 69.71; H, 8.72.

EXAMPLE 13 2,6-Di-t-butyl-4- (dimethyl-2, 3-dimethoxyphenylsilyl) methyloxy!phenol (Compund M)

Preparation as above using chloromethyl (dimethyl)-2,3-dimethoxy phenyl siland (11.3 g, 46 mmole) as the silane to give a white solid, mp 94.5-96C.

Anal. Calcd for C25 H38 O4 Si: C, 69.72; H, 8.89 Found: C, 69.84; H, 8.91.

EXAMPLE 14 2,6-Di-t-butyl-4- (dimethyl-4-t-butylphenylsilyl) methyloxy!phenol (Compound N)

Preparation as above using 4-t-Bulylphenyl chloromethyl dimethyl silane (6.2 g, 25.7mmole) as the silane to give the product as a white solid, mp 114-115 C.

Anal. Calcd for C27 H42 O2 Si: C, 76.00; H, 9.92 Found: C, 75.94; H, 10.13.

EXAMPLE 15 2,6-Di-t-butyl-4- (benzyldimethylsilyl) methyloxy!phenol (Compound O)

Preparation as above using benzyl chloromethyl dimethyl silane (7.13 g, 35.9 mmole) as the silane to give the product as a white solid, mp 76-77 C.

Anal. Calcd for C24 H36 O2 Si: C, 74.95; H, 9.43 Found: C, 74.94; H, 9.36.

The following compounds can be prepared by procedures analogous to those described above in Examples 1-15:

2,6-di-t-butyl-4 (triethylsilyl)methylthio!phenol

2,6-di-t-butyl-4 (diethylphenylsilyl)methylthio!phenol

2,6-di-t-butyl-4 (tripropylsilyl)methylthio!phenol

2,6-di-t-butyl-4 (dipropylphenylsilyl)methylthio!phenol

2,6-di-t-butyl-4 (triisopropylsilyl)methylthio!phenol

2,6-di-t-butyl-4 (diisopropylphenylsilyl)methylthio!phenol

2,6-di-t-butyl-4 (tributylsilyl)methylthio!phenol

2,6-di-t-butyl-4 (dibutylphenylsilyl)methylthio!phenol

2,6-di-t-butyl-4 (triisobutylsilyl)methylthio!phenol

2,6-di-t-butyl-4 (diisobutylphenylsilyl)methylthio!phenol

2,6-di-t-butyl-4 (tri-t-butylsilyl)methylthio!phenol

2,6-di-t-butyl-4 (di-t-butylphenylsilyl)methylthio!phenol

2,6-di-methyl-4 (trimethylsilyl)methylthio!phenol

2,6-di-methyl-4 (dimethylphenylsilyl)methylthio!phenol

2,6-di-methyl-4 (dibutylphenylsilyl)methylthio!phenol

2,6-di-methyl-4 (tri-t-butylsilyl)methylthio!phenol

2,6-di-methyl-4 (di-t-butylphenylsilyl)methylthio!phenol

2,6-di-ethyl-4 (trimethylsilyl)methylthio!phenol

2,6-di-ethyl-4 (dimethylphenylsilyl)methylthio!phenol

2,6-di-ethyl-4 (tri-t-butylsilyl)methylthio!phenol

2,6-di-ethyl-4 (di-t-butylphenylsilyl)methylthio!phenol

2,6-di-propyl-4 (trimethylsilyl)methylthio!phenol

2,6-di-propyl-4 (dimethylphenylsilyl)methylthio!phenol

2,6-di-isopropyl-4 (trimethylsilyl)methylthio!phenol

2,6-di-isopropyl-4 (dimethylphenylsilyl)methylthio!phenol

2,6-di-butyl-4 (trimethylsilyl)methylthio!phenol

2,6-di-butyl-4 (dimethylphenylsilyl)methylthio!phenol

2,6-dimethyl-4 (trimethylsilyl)methyloxy!phenol

2,6-dimethyl-4 (dimethylphenylsilyl)methyloxy!phenol

2,6-dibutyl-4 (triethylsilyl)methyloxy!phenol

2,6-dibutyl-4 (diethylphenylsilyl)methyloxy!phenol

2,6-di-t-butyl-4 (trimethylsilyl)methyloxy!phenol

2,6-di-t-butyl-4 (dimethylphenylsilyl)methyloxy!phenol.

A general synthetic scheme for preparing compounds of formula 1 wherein Z is methylene is set forth in Scheme B, wherein all substituents, unless otherwise indicated, are previously defined. ##STR12##

In general, a phenol of structure 1b can be prepared according to Scheme B in a two-step process. In step a, the appropriate haloalkylenesilane of structure 3 is reacted with magnesium metal in a suitable aprotic solvent, such as ethyl ether, in order to form the magnesium halide salt. The magnesium halide salt (Grignard reagent) is then reacted with the appropriate 3,5-dialkyl-4-hydroxy-benzaldehyde of structure 4 (or a suitably protected derivative) to give the alcohol of structure 5. In step b, the alcohol of structure 5 can be reduced to the desired phenol of structure 1b by a variety of reduction techniques and procedures as are well known and appreciated in the art. For example, the alcohol of structure 5 can be reduced by means of a Birch reduction by reacting it with sodium in liquid ammonia.

Starting materials for use in the general synthetic procedures outlined in Scheme B are readily available or can readily be prepared according to standard techniques and procedures. Where necessary to prevent undesired side reactions, the 1-phenol functionality of the 3,5-dialkyl-4-hydroxy-benzaldehyde of structure 4 in Scheme B may be blocked prior to the Grignard reaction with a standard phenol blocking agent as described previously in Scheme A.

The following example presents a typical synthesis as described in Scheme B. This example is understood to be illustrative only and is not intended to limit the scope of the present invention in any way.

EXAMPLE 16 2,6-Dimethyl-4 2-(trimethylsilyl)ethyl!phenol (Compound P)

Step a: Mix magnesium turnings (240 mg, 10 mmol) and anhydrous ethyl ether under an inert atmosphere. Add a solution of chloromethyltrimethylsilane (1.9 g, 10 mmol) in anhydrous ethyl ether. Stir until the magnesium metal dissolves. Add a solution of 3,5-dimethyl-4-hydroxybenzaldehyde (1.5 g, 10 mmol) in anhydrous ethyl ether. Stir until reaction is complete. Cool the reaction mixture to 0 C. and add saturated ammonium chloride solution. Separate the ether layer, wash with water and dry (MgSO4). Evaporate to give 4-hydroxy-3,5-dimethyl-α- (trimethylsilyl)-methyl!benzenemethanol and purify by silica gel chromatrography.

Step b: Mix sodium metal (520 mg, 22.6 mmol) and liquid ammonia (13 mL). To this solution add, by dropwise addition, a solution of 4-hydroxy-3,5-dimethyl-α- (trimethylsilyl)-methyl!benzenemethanol (2.22 g, 10 mmol) in ethyl alcohol (O.5 g) and ethyl ether (5 ml). After the blue color disappears, cautiously add water (13 mL), extract with ethyl ether, dry (MgSO4), and evaporate the solvent. Purify the residue by silica gel chromatography to yield the title compound.

Alternatively, compounds of formula (1) wherein Z is methylene can be prepared according to the procedure set forth in Scheme C, wherein all substituents, unless otherwise indicated, are previously described. ##STR13##

In general, a phenol of structure 1b can be prepared by first reacting the appropriate haloalkylenesilane of structure 3 with magnesium metal in an suitable aprotic solvent, such as ethyl ether, in order to form the magnesium halide salt. The magnesium halide salt (Grignard Reagent) is then reacted with the appropriate 3,5-dialkyl-4-hydroxy-benzylhalide of structure 6 (or a suitably protected derivative) to give the desired phenol of structure 1b.

Starting materials for use in the general synthetic procedures outlined in Scheme C are readily available or can readily be prepared according to standard techniques and procedures. For example, the preparation of 3,5-dimethyl-4-acetoxy-benzylbromide is described in Tetrahedron 33, 3097-103 (1977). 3,5-Dimethyl-4-acetoxy-benzylbromide can be converted to the corresponding phenolic starting material by standard hydrolytic procedures.

Where necessary to prevent undesired side reactions, the 1-phenol functionality of the 3,5-dialkyl-4-hydroxy-benzylhalide of structure 6 in Scheme C may be blocked prior to the Grignard reaction with a standard phenol blocking agent as described previously in Scheme A.

The following example presents a typical syntheses as described in Scheme C. his example is understood to be illustrative only and is not intended to limit the scope f the present invention in any way.

EXAMPLE 17 2,6-diethyl-4- 2-(trimethylsilyl)ethyl!-phenol (Compound Q)

Mix magnesium turnings (240 mg, 10 mmol) and anhydrous ethyl ether under an inert atmosphere. Add a solution of chloromethyltrimethylsilane (1.9 g, 10 mmol) in anhydrous ethyl ether. Stir until the magnesium metal dissolves. Add a solution of 4-bromomethyl-2,6-diethylphenol (2.43g, 10mmol) in anhydrous ethyl ether and reflux the mixture until the reaction is complete. Pour onto a mixture of ice/hydrochloric acid and separate the layers. Wash the ethereal layer with water, dry (MgSO4) and evaporate to give the title compound which is purified by silica gel chromatography.

The following compounds can be prepared by procedures analogous to those described above in Example 17:

2,6-dipropyl-4- 2-(trimethylsilyl)ethyl!-phenol

2,6-dipropyl-4- 2-(dimethylphenylsilyl)ethyl!-phenol

2,6-diisopropyl-4- 2-(trimethylsilyl)ethyl!-phenol

2,6-diisopropyl-4- 2-(dimethylphenylsilyl)ethyl!-phenol

2,6-diisobutyl-4- 2-(trimethylsilyl)ethyl!-phenol

2,6-diisobutyl-4- 2-(dimethylphenylsilyl)ethyl!-phenol

2,6-dibutyl-4- 2-(trimethylsilyl)ethyl!-phenol

2,6-dibutyl-4- 2-(dimethylphenylsilyl)ethyl!-phenol

2,6-di-t-butyl-4- 2-(trimethylsilyl)ethyl!-phenol

2,6-di-t-butyl-4- 2-(dimethylphenylsilyl)ethyl!-phenol

2,6-di-t-butyl-4- 2-(tri-t-butylsilyl)ethyl!-phenol

2,6-di-t-butyl-4- 2-(di-t-butylphenylsilyl)ethyl!-phenol

5 2,6-dimethyl-4- 2-(trimethylsilyl)ethyl!-phenol

2,6-dimethyl-4- 2-(dimethylphenylsilyl)ethyl!-phenol.

It is understood that compounds of formula (1) may exist in various stereoisomeric forms. All stereoisomeric forms which are consistent with the above structural formulas, as interpreted according to standard conventions for expressing stereoisomeric structure, are intended to be included within the scope of the present invention.

Compounds of formula (1), e.g. 2,6-di-alkyl-4-silyl-phenols, are known in the art. Specifically, compounds of formula (1) are described in U.S. Pat. No. 5,155,250. Preferred compounds of formula (1) are those in which R1 and R2 are C4 alkyl group, R3 and R4 are a C1 alkyl group, A is a C1 alkylene group, and R5 is --(CH2)n --(Ar) where n is 0 and Ar is phenyl unsubstituted or substituted with one to three substituents selected from the group consisting of hydroxy, methoxy, ethoxy, chloro, fluoro or C1 -C6 alkyl. More preferred is the compound 2,6-di-t-butyl-4 (dimethylphenyl-silyl)methyl!-thio-phenol.

As used herein, the term "patient" refers to warm-blooded animals or mammals, including rabbits and humans, who are in need of lowering plasma cholesterol levels or in need of lowering plasma LDL levels.

Hypercholesterolemia is a disease state characterized by the excessive cholesterol levels in the blood. The identification of patients with hypercholesterolemia and who are in need of treatment is well within the ability and knowledge of one skilled in the art. For example, individuals who are either suffering from clinically significant hypercholesterolemia or who are at risk of developing clinically significant hypercholesterolemia are patients in need of treatment. A clinician skilled in the art can readily determine, by the use of clinical tests, physical examination and medical/family history, if an individual is a patient in need of treatment for hypercholesterolemia.

An effective amount of a compound of formula (1) is an amount which is effective in inhibiting development or growth of hypercholesterolernia in a patient in need thereof. As such, successful treatment of a patient for hypercholesterolemia is understood to include effectively reducing or lowering serum cholesterol levels in a patient's blood and does not necessarily indicate a total elimination of the cholesterol. It is further understood and appreciated by those skilled in the art that successful treatment or hypercholesterolemia includes the use as a prophylactic to prevent clinically significant elevated levels of serum cholesterol.

An effective amount of a compound of formula (1) can be readily determined by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the effective dose, a number of factors are considered including, but not limited to: the species of patient; its size, age, and general health; the specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; and the use of concomitant medication.

An effective amount of a compound of formula (1) will generally vary from about 1 milligram per kilogram of body weight per day (mg/kg/day) to about 5 grams per kilogram of body weight per day (gm/kg/day). A daily dose of from about 1 mg/kg to about 500 mg/kg is preferred.

In effecting treatment of a patient, a compound of formula (1) can be administered in any form or mode which makes the compound bioavailable in effective amounts, including oral and parenteral routes. For example, the compound can be administered orally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, and the like. Oral administration is generally preferred. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the disease state to be treated, the stage of the disease, and other relevant circumstances.

A compound of formula (1) can be administered in the form of pharmaceutical compositions or medicaments which are made by combining a compound of formula (1) with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are determined by the chosen route of administration, and standard pharmaceutical practice.

The pharmaceutical compositions or medicaments are prepared in a manner well known in the pharmaceutical art. The carrier or excipient may be a solid, semi-solid, or liquid material which can serve as a vehicle or medium for the active ingredient. Suitable carriers or excipients are well known in the art. The pharmaceutical composition may be adapted for oral or parenteral use and may be administered to the patient in the form of tablets, capsules, suppositories, solution, suspensions, or the like.

The pharmaceutical compositions may be administered orally, for example, with an inert diluent or with an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, a compound of formula (1) may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These preparations should contain at least 4% of a compound of formula (1), the active ingredient, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit. The amount of the active ingredient present in compositions is such that a unit dosage form suitable for administration will be obtained.

The tablets, pills, capsules, troches and the like may also contain one or more of the following adjuvants: binders, such as microcrystalline cellulose, gum tragacanth or gelatin; excipients, such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like; lubricants, such as magnesium stearate or Sterotex; glidants, such as colloidal silicon dioxide; and sweetening agents, such as sucrose or saccharin may be added or flavoring agents, such as peppermint, methyl salicylate or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the active ingredient, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.

For the purpose of parenteral administration, a compound of formula (1) may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of a compound of the invention, but may be varied to be between 0.1 and about 50% of the weight thereof. The amount of the active ingredient present in such compositions is such that a suitable dosage will be obtained.

The solutions or suspensions may also include one or more of the following adjuvants depending on the solubility and other properties of a compound of formula (1): sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diamlnetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of toxicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

The following examples illustrate the use of compounds of formula (1) according to the present invention. These examples are illustrative only and are not intended to limit the scope of the invention in any way.

EXAMPLE 18 Reduction of Cholesterol Levels of 1% Cholesterol-Fed New Zealand White Rabbits by Concurrent Administration of 0.5% Compound A (2,6-Di-t-butyl-4 (dimethylphenylsilyl)methylthio!phenol)

New Zealand White (NZW) rabbits (female, aged 3-4 months, weighing less than 3 kg) six in each group, were fed a control diet of 1% cholesterol (100 g rabbit chow daily containing 1 g cholesterol) or a diet of 1% cholesterol/0.5% drug (100 g rabbit chow daily containing 1 g cholesterol and 0.5 g Compound A). After 56 days, the rabbits were sacrificed by intravenous injection of pentobarbital. Plasma or serum was collected and cholesterol levels were determined using the enzymatic method of Mao, et al., Clin. Chem. (1983) 29: 1890-1897. The results obtained are summarized in Table 1, below:

______________________________________     Control (n = 6)                  Compound A (n = 6)DAY       Cholesterol (mg/dl)                  Cholesterol (mg/dl)______________________________________0         61  9    59  814        1138  134                  684  9928        1908  256                   954  12642        2175  376                  1118  16456        2432  475                  1035  152______________________________________

At day 56, the reduction of serum cholesterol was 57% by the administration of Compound A.

EXAMPLE 19 Reduction of Cholesterol levels of 0.2% Cholesterol-Fed New-Zealand White Rabbits by Concurrent Administration of 0.4% Compound A

NZW rabbits (female, aged 3-4 months, weighing less than 3 Kg), six in each group, were fed a control diet of 0.2% cholesterol (100 g rabbit chow daily containing 0.2 g cholesterol) or a diet of 0.2% cholesterol/0.4% drug (100 g rabbit chow daily containing 0.2 g cholesterol and 0.4 g Compound A). After 56 days, the rabbits were sacrificed by intravenous injection of pentobarbital. Plasma or serum was collected and cholesterol levels were determined using the enzymatic method of Mao, et al., Clin. Chem. (1983) 29: 1890-1897. The results obtained are summarized in Table 2 below:

______________________________________     Control (n = 6)                  Compound A (n = 6)DAY       Cholesterol (mg/dl)                  Cholesterol (mg/dl)______________________________________0         73  10   66  87         325  43  154  1714        587  71  223  3228        898  126 291  5942        988  147 357  8956        941  163  337  100______________________________________

The results obtained demonstrate that administration of Compound A for 56 days produced significant cholesterol lowering in 0.2% cholesterol-fed rabbits. The reduction of cholesterol was 64%.

EXAMPLE 20 Reduction of Cholesterol levels of 0.2% Cholesterol-Fed New Zealand White Rabbits by Concurrent Administration of 0.4% Drug

NZW rabbits (female, aged 3-4 months, weighing less than 3 Kg), six in each group, were fed a control diet of 0.2% cholesterol (100 g rabbit chow daily containing 0.2 g cholesterol) or a diet of 0.2% cholesterol/0.4% drug (100 g rabbit chow daily containing 0.2 g cholesterol and 0.4 g of drug). For Compound A, the rabbits were sacrificed by intravenous injection of pentobarbital after 56 days. For Compound G, K, E and H, the rabbits were sacrificed by intravenous injection of pentobarbital after 7 days. Plasma or serum was collected and cholesterol levels were determined using the enzymatic method of Mao, et al., Clin. Chem. (1983) 29: 1890-1897. Liver weight and body weights were determined. Serum HDL and LDL cholesterol levels were determined using gel filtration HPLC modified from Kieft, K. A., et al., J. Lipid Res., 32: 859-861 (1991), using Roche enzymatic cholesterol reagents. Triglyceride levels were determined by Cobas Automated Analyzer using Roche enzymatic reagents.

The results obtained are summarized in Table 2 below:

______________________________________   liver wt/           cholesterol                    LDL    HDL   body wt (total)  cholesterol                           cholesterolCompound   ratio   % Control                    % Control                           % Control                                  triglycerides______________________________________A       120%    52%      42%    75%    366%G       104%    72%      69%    81%    104%K       90%     77%      61%    217%   131%E       93%     87%      89%    109%   82%H       110%    54%      66%    123%   73%______________________________________
EXAMPLE 21 Reduction in Cholesterol Levels of Normolipidemic New Zealand Rabbits by Concurrent Administration of 0.5% Compound A

New Zealand White rabbits (female, aged 3-4 months, weighing less than 3 kg), four in each group, were fed a normal diet (100 g rabbit chow daily) or a diet of 0.5% drug (100 g rabbit chow daily containing 0.5 g Compound A). Serum was collected and cholesterol levels were determined according to the method of Mao, et al., Clin. Chem. (1983) 29: 1890-1897. The results are summarized in Table 3 below:

______________________________________     Control (n = 4)                  Compound A (n = 4)DAY       Cholesterol (mg/dl)                  Cholesterol (mg/dl)______________________________________0         47.0  11 45.3  48         90.0  13 69.7  614        87.3  7  54.8  823        81.5  68 58.3  6______________________________________

As compared to control rabbits at day 23, the level of cholesterol was significantly reduced by about 29%.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3129262 *Oct 8, 1962Apr 14, 1964Consolidation Coal CoReduction of organic thiocyanates
US3328450 *Jan 9, 1963Jun 27, 1967Dow CorningSilylalkyl phenols
US3576883 *Jun 30, 1969Apr 27, 1971Consolidation Coal CoAlkylidenedithiobisphenols
US3586705 *Aug 15, 1968Jun 22, 1971Midland Silicones LtdOxidation retarders
US3786100 *Dec 10, 1971Jan 15, 1974Continental Oil CoKeto substituted alkylidenedithiobisphenols
US3862332 *Nov 19, 1969Jan 21, 1975Dow Chemical CoMethod of lowering serum cholesterol
US3897500 *May 29, 1973Jul 29, 1975Continental Oil CoAlkylidenedithiobisphenols
US4374742 *May 29, 1981Feb 22, 1983Ciba-Geigy CorporationNovel lubricant additives
US4663314 *May 6, 1986May 5, 1987Shionogi & Co., Ltd.Ether compounds carrying substituted silyl group
US4670421 *Jul 12, 1982Jun 2, 1987American Cyanamid CompanyAntiatherosclerotic silanes
US4719237 *Jan 28, 1986Jan 12, 1988Merrell Dow Pharmaceuticals Inc.Cardiac antiarrythmic method employing probucol
US4734527 *Oct 17, 1986Mar 29, 1988Merrell Dow Pharmaceuticals Inc.Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol
US4772363 *Jan 14, 1987Sep 20, 1988Merrell Dow Pharmaceuticals Inc.Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol by electrocatalysis
US4861443 *Jun 22, 1988Aug 29, 1989Merrell Dow Pharmaceuticals Inc.Process for preparing 4,4'-isopropylidenedithio-bis-(2,6-di-tertiarybutylphenol) by electrocatalysis
US4870101 *Feb 18, 1988Sep 26, 1989Merrell Dow Pharmaceuticals Inc.Tetraethylthiuram disulfide
US4900757 *Dec 8, 1988Feb 13, 1990Merrell Dow Pharmaceuticals Inc.Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
US4975467 *Mar 26, 1990Dec 4, 1990Merrell Dow Pharmaceuticals Inc.Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions
US5008421 *Oct 10, 1989Apr 16, 1991Aristech Chemical CorporationUseful comonomers for olefins in high molecular weight copolymers
US5061734 *May 9, 1990Oct 29, 1991Merrell Dow Pharmaceuticals Inc.Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
US5112870 *Jul 22, 1991May 12, 1992Merrell Dow Pharmaceuticals Inc.Enhancing activity of protective ocular enzymes to prevent cataracts
US5117028 *Sep 27, 1991May 26, 1992Hoechst AktiengesellschaftCatalysis with hexachloroplatinic acid; hydrosilation
US5155250 *Jul 5, 1990Oct 13, 1992Merrell Dow Pharmaceuticals Inc.2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
US5217870 *Apr 28, 1989Jun 8, 1993Biogen, Inc.Monoclonal antibodies against CDX
US5272263 *Dec 18, 1989Dec 21, 1993Biogen, Inc.DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5281738 *Sep 2, 1992Jan 25, 1994Merrell Dow Pharmaceuticals Inc.Anticholesterol agents
US5292850 *Sep 11, 1992Mar 8, 1994Enichem SynthesisPolysiloxanic stabilizers containing sterically hindered phenol group and reactive groups
US5304668 *Jun 15, 1993Apr 19, 1994Merrell Dow PharmaceuticalsBis-[4-(2,6-di-alkyl)phenolisilane derivatives as antiatherosclerotic agents
US5356917 *Aug 24, 1993Oct 18, 1994Eli Lilly And CompanyAntiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals
US5367056 *Mar 23, 1993Nov 22, 1994Biogen, Inc.Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)
US5380747 *Oct 30, 1992Jan 10, 1995Emory UniversityTreatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5401883 *Jul 7, 1993Mar 28, 1995Merrell Dow Pharmaceuticals Inc.Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol and 4,4'-isopropylidenedithio-bis-(2,6-di-tertiarybutylphenol)
US5532400 *Dec 12, 1994Jul 2, 1996Merrell Pharmaceuticals Inc.2,6-di-alkyl-4-silyl-phenols as antiatheroscelerotic agents
AU9460533A * Title not available
DE3604781A1 *Feb 13, 1986Aug 27, 1987Schering AgNovel silanes, their preparation, and insecticidal compositions containing these compounds
EP0372542A2 *Dec 7, 1989Jun 13, 1990Merrell Dow Pharmaceuticals Inc.Hypocholesterolemic and antiatherosclerotic uses of bis (3,5-di-tertiary-butyl-4-hydroxyphenylthio) methane
EP0374048A1 *Dec 13, 1989Jun 20, 1990Tanabe Seiyaku Co., Ltd.4-Aminophenol derivatives and processes for preparing the same
EP0464844A1 *Jul 5, 1991Jan 8, 1992Merrell Dow Pharmaceuticals Inc.Novel bis (4-(2,6-di-alkyl)phenol)silane derivatives as antiatherosclerotic agents and as antioxidants
EP0464852A1 *Jul 5, 1991Jan 8, 1992Merrell Pharmaceuticals Inc.Novel 2,6-di-alkyl-4-silyl-phenols as antiatherosclerotic agents and as antioxidants
FR2308372A2 * Title not available
GB1199871A * Title not available
GB2158450A * Title not available
JPH07330595A * Title not available
WO1993012089A1 *Dec 18, 1992Jun 24, 1993Merz & Co Gmbh & CoNew bht ether compounds and their use as hypolipidemic and antiatherosclerotic drugs
WO1993021914A1 *Apr 30, 1993Nov 11, 1993Sampath ParthasarathySoluble analogs of probucol
WO1994005333A1 *Aug 27, 1993Mar 17, 1994Isis Pharmaceuticals IncOligonucleotide modulation of cell adhesion
WO1994009772A1 *Nov 1, 1993May 11, 1994Univ EmoryDithiocarbamates for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases
WO1994011027A1 *Nov 15, 1993May 26, 1994Univ WashingtonPeripheralization of hematopoietic stem cells
WO1994014786A1 *Dec 16, 1993Jul 7, 1994Thomas Henry BrownPiperidine derivatives as calcium channel antagonists
WO1994016094A2 *Jan 7, 1994Jul 21, 1994Biogen IncRecombinant anti-vla4 antibody molecules
WO1994017828A2 *Feb 9, 1994Aug 18, 1994Biogen IncTreatment for insulin dependent diabetes
WO1995004749A1 *Aug 5, 1994Feb 16, 1995Clarence F BennettOligomers for modulating metabolic function
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7515453Jun 23, 2006Apr 7, 2009Metaram, Inc.Integrated memory core and memory interface circuit
US7581127Oct 20, 2006Aug 25, 2009Metaram, Inc.Interface circuit system and method for performing power saving operations during a command-related latency
US7599205Mar 25, 2008Oct 6, 2009Metaram, Inc.Methods and apparatus of stacking DRAMs
US7730338Apr 29, 2008Jun 1, 2010Google Inc.Interface circuit system and method for autonomously performing power management operations in conjunction with a plurality of memory circuits
US7761724Apr 29, 2008Jul 20, 2010Google Inc.Interface circuit system and method for performing power management operations in conjunction with only a portion of a memory circuit
US7879967 *Apr 3, 2008Feb 1, 2011Bayer Materialscience AgModified polycarbonates, polyester carbonates and polyesters having improved elongation behavior and flame resistance
US8773937Dec 9, 2011Jul 8, 2014Google Inc.Memory refresh apparatus and method
WO2005037250A1 *Oct 18, 2004Apr 28, 2005Amylin Pharmaceuticals IncSelf emulsifying drug delivery systems for hydrophobic therapeutic compounds
WO2005037251A1 *Oct 18, 2004Apr 28, 2005Amylin Pharmaceuticals IncSelf-emulsifying drug delivery systems for hydrophobic therapeutic compounds
WO2005037291A1 *Oct 18, 2004Apr 28, 2005Amylin Pharmaceuticals IncSilyl phenol for promoting vascular health
WO2005039596A1 *Oct 18, 2004May 6, 2005Amylin Pharmaceuticals IncSilyl phenols for promoting vascular health
Classifications
U.S. Classification514/63, 556/449, 556/447
International ClassificationA61K31/695, C07F7/08
Cooperative ClassificationA61K31/695, C07F7/0818
European ClassificationA61K31/695, C07F7/08C6D
Legal Events
DateCodeEventDescription
Mar 10, 2011FPAYFee payment
Year of fee payment: 12
Mar 1, 2010ASAssignment
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVENTIS HOLDINGS INC.;REEL/FRAME:024006/0046
Owner name: AVENTISUB II INC.,DELAWARE
Effective date: 20081231
Feb 24, 2010ASAssignment
Owner name: AVENTIS HOLDINGS INC.,DELAWARE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVENTISUB INC.;REEL/FRAME:023985/0029
Effective date: 20081231
Feb 23, 2010ASAssignment
Effective date: 20081231
Owner name: AVENTISUB INC.,DELAWARE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVENTIS INC.;REEL/FRAME:023973/0163
Feb 8, 2008ASAssignment
Owner name: AVENTIS INC., NEW JERSEY
Free format text: CHANGE OF NAME;ASSIGNOR:MERRELL PHARMACEUTICALS INC.;REEL/FRAME:020478/0732
Effective date: 20051027
Feb 6, 2008ASAssignment
Owner name: MERRELL PHARMACEUTICALS INC., NEW JERSEY
Free format text: CHANGE OF NAME;ASSIGNOR:MERRELL DOW PHARMACEUTICALS INC.;REEL/FRAME:020468/0392
Effective date: 19950915
Feb 5, 2008ASAssignment
Owner name: MERRELL DOW PHARMACEUTICALS INC., OHIO
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAO, SIMON J.T.;YATES, MARK T.;PARKER, ROGER A.;REEL/FRAME:020462/0615
Effective date: 19931210
Mar 30, 2007FPAYFee payment
Year of fee payment: 8
Apr 1, 2003FPAYFee payment
Year of fee payment: 4